Danaher Corp /De/ - Jun 22, 2021 Form 4 Insider Report for Codex DNA, Inc. (TBIO)

Role
10%+ Owner
Signature
Danaher Corporation /s/ James F. O'Reilly, Vice President, Deputy General Counsel and Secretary
Stock symbol
TBIO
Transactions as of
Jun 22, 2021
Transactions value $
$0
Form type
4
Date filed
6/24/2021, 04:51 PM
Previous filing
Jun 24, 2021
Next filing
Sep 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction TBIO Common Stock +Conversion of derivative security $0 +2,294,157 $0.00 2,294,157 Jun 22, 2021 By Danaher Innovation Center LLC F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TBIO Series A Preferred Stock -Conversion of derivative security $0 -1,751,999 -100% $0.00 0 Jun 22, 2021 Common Stock 1,751,999 By Danaher Innovation Center LLC F1, F2
transaction TBIO Series A-1 Preferred Stock -Conversion of derivative security $0 -542,158 -100% $0.00 0 Jun 22, 2021 Common Stock 542,158 By Danaher Innovation Center LLC F1, F2

Danaher Corp /De/ is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Each share of Series A Preferred Stock and Series A-1 Preferred Stock (collectively, the "Preferred Stock"), par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Preferred Stock into Common Stock had no expiration date.
F2 Held by Danaher Innovation Center LLC. Danaher Innovation Center LLC is an indirect, wholly owned subsidiary of Danaher Corporation. The address of Danaher Innovation Center LLC is 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC 20037.